Salmeterol metered dose inhaler (MDI) propelled by hydrofluoroalkane (HFA) is non-inferior to salmeterol chlorofluorocarbon (CFC) propelled MDI in paediatic patients with persistent asthma

N. Chopra, M. Rimmer, M. Williams, M. Jenkins, on Behalf of Int Study Team SMO30007 (Greenford, United Kingdom)

Source: Annual Congress 2004 - Improvements in delivery of inhaled agents
Session: Improvements in delivery of inhaled agents
Session type: Thematic Poster Session
Number: 3580
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
N. Chopra, M. Rimmer, M. Williams, M. Jenkins, on Behalf of Int Study Team SMO30007 (Greenford, United Kingdom). Salmeterol metered dose inhaler (MDI) propelled by hydrofluoroalkane (HFA) is non-inferior to salmeterol chlorofluorocarbon (CFC) propelled MDI in paediatic patients with persistent asthma. Eur Respir J 2004; 24: Suppl. 48, 3580

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Non-inferior efficacy of hydrofluoroalkane (HFA) salmeterol (SALM) metered dose inhaler (MDI) compared to salmeterol chlorofluorocarbon (CFC) in adolescent & adult patients with persistent asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 583s
Year: 2004

Non-inferiority comparison of ipratropium-salbutamol HFA (IB/SAL-HFA) pMDI with ipratropium salbutamol CFC (IF/SAL-CFC) pMDI in patients with COPD
Source: Eur Respir J 2007; 30: Suppl. 51, 611s
Year: 2007

Formoterol hydrofluoroalkane (HFA) pMDI has as rapid an onset of action as salbutamol HFA pMDI in asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 285s
Year: 2003

Non-inferiority comparison of budesonide HFA (BUD-HFA) pMDI with budesonide CFC (BUD-CFC) pMDI in patients with persistent moderate asthma
Source: Annual Congress 2008 - Wider aspects of managing respiratory disease in primary care
Year: 2008


Non-inferiority comparison of formoterol HFA (FM-HFA) pMDI with formoterol CFC (FM-CFC) pMDI in patients with symptomatic asthma
Source: Eur Respir J 2007; 30: Suppl. 51, 358s
Year: 2007

Non inferiority comparison of salmeterol HFA (SM-HFA) pMDI with salmeterol CFC (SM-CFC) pMDI in patients with symptomatic asthma
Source: Eur Respir J 2007; 30: Suppl. 51, 357s
Year: 2007

A comparison of the efficacy of salmeterol/fluticasone propionate combination (SF) with beclometasone dipropionate (BDP) delivered via metered dose inhaler (MDI) in patients not well controlled on bronchodilators alone
Source: Eur Respir J 2001; 18: Suppl. 33, 53s
Year: 2001

Comparison of HFA fluticasone-formoterol combination pressurized meter dose inhaler (pMDI) and HFA budesonide-formoterol combination pMDI in patients with moderate to severe persistent asthma
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II
Year: 2010


Clinical equivalence of salmeterol/fluticasone propionate combination 50/100mcg b.i.d. delivered via DiskusÔ or CFC-free metered dose Inhaler (MDI) in children with asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 311s
Year: 2003

Formoterol via turbuhaler (F) versus salbutamol via pressurized metered-dose inhaler (SB) in acute exacerbations of COPD
Source: Eur Respir J 2001; 18: Suppl. 33, 425s
Year: 2001

Relative pulmonary bioavailability (BA) of fluticasone propionate/formoterol (FP/FORM) via pressurised metered-dose inhaler (pMDI) and a novel breath-triggered inhaler (BTI)
Source: International Congress 2017 – Pulmonary drug and devices delivery
Year: 2017


Assessment of relative potency of salbutamol administered via a metered-dose inhaler plus spacer or via a dry-powder inhaler in asthma patients
Source: Eur Respir J 2006; 28: Suppl. 50, 209s
Year: 2006

Comparability of formoterol dry powder (DPI) and metered dose inhalers (MDI) in asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 50s
Year: 2005

Pharmaceutical development of salmeterol HFA metered dose inhaler
Source: Eur Respir J 2004; 24: Suppl. 48, 582s
Year: 2004

Comparison of the efficacy and safety of ipratropium bromide (IB)/fenoterol hydrobromide (FEN) inhaled from a new soft mist inhaler (SMI) and from a conventional metered dose inhaler (MDI) in asthma patients
Source: Eur Respir J 2001; 18: Suppl. 33, 70s
Year: 2001

Comparison of proficiency of pressurized metered dose inhaler (pMDI) use with asthma control
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma
Year: 2008


QVAR pMDI is more cost effective than CFC-beclometasone dipropionate (BDP) pMDI in a real-life asthmatic population initiating ICS
Source: Annual Congress 2009 - Sustainability in treatment of COPD patients according to economics and quality of care
Year: 2009

Bronchodilator response to salbutamol administered through metered-dose inhaler plus spacer or dry-powder inhaler in asthmatic patients
Source: Eur Respir J 2001; 18: Suppl. 33, 101s
Year: 2001

Safety of beclomethasone HFA (HFA BDP) pMDI compared with beclomethasone CFC pMDI (CFC BDP) over 12 weeks
Source: Eur Respir J 2005; 26: Suppl. 49, 503s
Year: 2005

The novel budesonide HFA pMDI is clinically comparable to the conventional budesonide CFC pMDI in paediatric patients with asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 160s
Year: 2005